949568-47-2

Basic information

• Product Name: (R,E)-methyl 4-(3,4-dichlorophenyl)-4-phenylbut-2-enoate
• Synonyms: (R,E)-methyl 4-(3,4-dichlorophenyl)-4-phenylbut-2-enoate
• CAS NO: 949568-47-2
• Molecular Weight: 321.203
• Mol File: 949568-47-2.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: (R,E)-methyl 4-(3,4-dichlorophenyl)-4-phenylbut-2-enoate(CAS DataBase Reference)
• NIST Chemistry Reference: (R,E)-methyl 4-(3,4-dichlorophenyl)-4-phenylbut-2-enoate(949568-47-2)
• EPA Substance Registry System: (R,E)-methyl 4-(3,4-dichlorophenyl)-4-phenylbut-2-enoate(949568-47-2)

Safety Data

• Hazardous Substances Data: 949568-47-2(Hazardous Substances Data)

Upstream product

• 1198097-83-4 (E)-methyl 3-(3,4-dichlorophenyl)-3-phenylacrylate 
• 405-02-7 1,2-dichloro-4-diazoniumbenzene tetrafluoroborate 
• 103-26-4 Methyl cinnamate 
• 87802-71-9 (E)-methyl cinnamyl carbonate 
• 79175-35-2 3,4-dichlorophenylmagnesium bromide 
• 234084-70-9 methyl (E)-2-diazo-4-(3,4-dichlorophenyl)-3-butenoate 
• 6287-38-3 3,4-dichlorobenzaldehyde 
• 127404-77-7 (E)-4-(3,4-dichlorophenyl)but-3-enoic acid 
• 501426-95-5 methyl (E,4R)-4-(2,5-cyclohexadienyl)-4-(3,4-dichlorophenyl)-2-butenoate 
• 949568-31-4 (R)-1,2-dichloro-4-(1-phenylallyl)benzene 
• 292638-85-8 acrylic acid methyl ester 

Downstream Products

• 304021-48-5 methyl (4R)-4-(3,4-dichlorophenyl)-4-phenylbutanoate 
• 155748-61-1 (4R)-(3,4-Dichlorophenyl)-3,4-dihydro-1(2H)-naphthalenone 
• 124379-29-9 (4S)-4-(3,4-dichlorophenyl)-1-tetralone 
• 147255-16-1 (4R)-4-(3,4-dichlorophenyl)-4-phenylbutanoic acid 

Relevant articles and documents

Two stereocentered HKR of anti -β,β′-diphenylpropanoxirane and anti -3-phenylethyloxiranes catalysed by Co(iii)(salen)-OAc complex: Enantioselective synthesis of (+)-sertraline and (+)-naproxen

The Co(III)(salen)OAc-catalyzed two stereocentered hydrolytic kinetic resolution (HKR) of anti-β,β′-diphenylmethyloxirane and anti-3-phenylethyloxiranes affords the corresponding anti-1,2-diols and oxiranes in high enantiomeric excess. The synthetic potential of this methodology is demonstrated by the enantioselective synthesis of (+)-sertraline, an antidepressant drug, and (+)-naproxen, an anti-inflammatory drug.

Iridium-catalyzed asymmetric allylic substitution with aryl zinc reagents

Thanks to iridium catalysis, arylzinc reagents undergo regioselective allylic substitution with very high enantioselectivity, when associated with phosphoramidite ligands.